Leave Your Message
North America, Europe, and Asia-Pacific are the three dominant consumption regions — with China and India emerging as both major producers and fast-growing consumers of pharmaceutical-grade plant extracts.
The pharmaceutical industry's shift toward plant-derived active pharmaceutical ingredients (APIs) is driven by several converging forces: consumer preference for natural health products, robust clinical evidence supporting phytochemicals, regulatory acceptance of botanical drugs, and the cost advantages of plant-based synthesis routes over synthetic chemistry. Plant extract powders — precisely standardized for active compound content — are now indispensable raw materials across drug discovery, OTC medicine, dietary supplements, functional foods, and cosmeceuticals.
Plant extract powders serve as active pharmaceutical ingredients (APIs) or co-actives in tablets, capsules, and injectables. Compounds like quercetin, berberine, and betulin demonstrate validated anti-inflammatory, antiviral, and anticancer mechanisms, enabling botanical drug development under FDA 21 CFR Part 312 and EMA botanical medicine guidelines.
High-purity powders such as mulberry leaf extract (DNJ content standardized) and stevia (steviol glycosides ≥98%) are formulated into blood sugar management supplements, weight management products, and functional beverages. The nutraceutical segment accounts for over 35% of total plant extract consumption globally.
Pharmaceutical researchers leverage standardized botanical extracts to study structure-activity relationships and improve bioavailability through nanoencapsulation, liposomal delivery, and solid dispersion technologies. Quercetin nanoparticles and betulin-loaded nanocarriers are active areas of clinical investigation for oncology and metabolic disease.
TCM-derived and Ayurvedic plant extracts are being standardized and integrated into modern integrative medicine protocols. Tamarind extract (10:1 concentration) and ellagic acid from pomegranate are gaining traction in evidence-based complementary oncology and cardioprotection programs in hospital settings across Asia and Europe.
Ellagic acid, quercetin, and betulin are prized for their skin-brightening, anti-aging, and barrier-repair properties. Pharmaceutical-grade purity ensures safety for topical drug-cosmetic hybrid formulations, including prescription creams and OTC serums targeting hyperpigmentation, eczema, and photoaging.
The animal health sector is adopting plant extract powders as antibiotic alternatives for livestock, poultry, and companion animals. Stevia-based sweeteners and magnesium glycinate are formulated into palatable veterinary supplements, while quercetin and ellagic acid are explored as natural anti-infective agents in aquaculture.
The industry is moving rapidly toward HPLC-verified, pharmacopoeia-aligned standardization. Buyers demand Certificates of Analysis specifying exact active compound percentages (e.g., quercetin ≥95%, betulin ≥98%), heavy metal limits, pesticide residue data, and microbial counts — mirroring pharmaceutical API quality standards.
Supercritical CO₂ extraction, ultrasonic-assisted extraction, and enzyme-assisted methods are replacing traditional solvent extraction, reducing environmental impact while improving yield and preserving thermolabile bioactives. Manufacturers investing in green extraction gain premium market positioning and regulatory favor in EU markets.
Artificial intelligence is being deployed across the supply chain — from predictive crop sourcing and real-time extraction optimization to AI-powered HPLC data analysis and automated batch release decisions. This digital transformation is compressing development timelines and dramatically reducing batch failure rates.
The FDA's Botanical Drug Guidance and EMA's herbal medicine monographs are creating clearer regulatory pathways. More plant extract-based NDAs and 505(b)(2) applications are being filed, legitimizing botanical APIs in mainstream pharmaceutical development and opening institutional procurement channels.
Genomics and microbiome research are enabling personalized supplement stacks where specific plant extract powders are dosed based on individual genetic profiles and gut microbiota composition. This trend is driving demand for ultra-pure, highly concentrated extracts suitable for precision micro-dosing applications.
Leading manufacturers are establishing direct contracts with GAP-certified farms, implementing blockchain-based traceability, and building in-house extraction and analytical capabilities. Vertical integration reduces supply chain risk, ensures raw material consistency, and provides competitive pricing — critical factors for pharmaceutical buyers.
Shaanxi Yuantai Biological Technology Co., Ltd. was established in 2014. Its headquarter is located in Xi'an and its factory is located in Weinan Economic and Technological Development Zone. The factory covers an area of 10,000+㎡.
At present, the company's main categories include: capsules, granules, tablets, solid beverages, soft candies and other OEM categories. YTBIO has 10+ years of production experience in the raw material field. The main categories include: herbal extracts, nutritional supplements, organic extract raw materials and cosmetic raw materials.
YTBIO is a comprehensive health food manufacturer. With its deep understanding of the raw material industry, it provides compounding solutions from raw materials to finished products, and supports professional solutions in product packaging, flexible application of ingredients, and product label design.
YTBIO's production facilities and equipment meet national standards, and the production process is strictly carried out in accordance with GMP requirements. Raw materials meet national standards, and after comprehensive inspection and quality control, the production process follows scientific protocols to ensure the safety, stability and effectiveness of every product.
The factory has standardized R&D rooms and inspection rooms, and a 100,000-level GMP purification workshop. Using professional production experience, leading equipment, and professional technology, strict standards have been set for every link. Each batch of products is checked and inspected before leaving the factory, ensuring quality control from raw materials to finished products.
In 10+ years of development, the company has continuously improved its corporate management level, strengthened quality management, and managed in accordance with international standardized quality management system requirements. We continuously improve the effectiveness of system operation and the company's management level to jointly promote rapid development.
To ensure product quality and production process standards, we have passed cGMP, FSSC22000, BRC, HACCP, ISO9001, ISO22000, HALAL, KOSHER, FDA, and EU & US organic certifications — providing pharmaceutical and healthcare customers with full regulatory assurance across global markets.
From plant extract raw material to finished, labeled product — YTBIO provides complete OEM solutions including capsules, granules, tablets, solid beverages, and soft candies.
OEM categories: Capsules, granules, tablets, solid beverages, etc. | OEM content: Raw materials, formula, packaging, label design, etc.
Within our solid beverage production facilities we are able to offer the production of instant teas, granular beverages and pack them directly into finished products or in separate operations, for example:
Use the highest quality plant raw materials from reliable suppliers, produce and process in our own factory, providing one-stop service. Extract and process with high technical standards to retain the highest quality ingredients of raw materials. Produce products such as capsules, tablets and solid drinks.
Whether you need pharmaceutical-grade APIs, nutraceutical actives, or full OEM manufacturing services, YTBIO's team of experts is ready to support your product development from concept to certified finished product.
Request a Quote & Sample →
